<p>Founders Capital Management LLC 在最近向證券交易委員會提交的文件中表示，在第二季度將其在再生元製藥公司（NASDAQ:REGN - 免費報告）的持股增加了 7.0%。這家機構投資者在該季度額外購買了 538 股後，持有該生物製藥公司 8,274 股股票。再生元製藥佔 Founders Capital Management LLC 投資組合的 0.7%，是其第 25 大持股。到最近一個季度末，Founders Capital Management LLC 在再生元製藥的持股價值為 4,344,000 美元。</p>
<ul>
<li>大熊：3 只接近一年低點的股票，可能在 2025 年大幅上漲</li>
</ul>
<p>其他一些對沖基金和機構投資者也調整了對 REGN 的持股。GAMMA Investing LLC 在第一季度將其在再生元製藥的持股增加了 89,825.0%。GAMMA Investing LLC 目前持有 815,620 股該生物製藥公司的股票，價值 517,291,000 美元，此前在上個季度額外購買了 814,713 股。Nuveen LLC 在第一季度購買了再生元製藥的新頭寸，價值 343,764,000 美元。Pacer Advisors Inc.在第一季度將其在再生元製藥的持股增加了 2,296.9%。Pacer Advisors Inc.目前持有 407,370 股該生物製藥公司的股票，價值 258,366,000 美元，此前在上個季度額外購買了 390,374 股。Assenagon Asset Management S.A.在第一季度將其在再生元製藥的持股增加了 171.0%。Assenagon Asset Management S.A.目前持有 481,389 股該生物製藥公司的股票，價值 305,311,000 美元，此前在上個季度額外購買了 303,785 股。最後，Universal Beteiligungs und Servicegesellschaft mbH 在第四季度購買了再生元製藥的新頭寸，價值 127,215,000 美元。目前 83.31% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>REGN 最近受到了一些分析師報告的關注。富國銀行將再生元製藥的評級從 “增持” 下調至 “持平”，併為該公司設定了 580.00 美元的目標價。在 8 月 1 日星期五的報告中，Truist Financial 將再生元製藥的目標價從 940.00 美元下調至 812.00 美元，並在 8 月 11 日星期一的報告中為該公司設定了 “買入” 評級。花旗集團在 8 月 1 日星期五的研究報告中重申了 “買入” 評級，併為再生元製藥的股票發佈了 650.00 美元的目標價。傑富瑞金融集團在 8 月 27 日星期三的研究報告中將再生元製藥的目標價從 813.00 美元上調至 831.00 美元，並給予該公司 “買入” 評級。最後，Argus 在 6 月 30 日星期一的研究報告中將再生元製藥的評級從 “買入” 下調至 “持有”。三位研究分析師對該股票給予了強烈買入評級，十八位給予了買入評級，六位給予了持有評級，一位給予了賣出評級。根據 MarketBeat，該公司目前的共識評級為 “適度買入”，共識目標價為 817.67 美元。</p>
<ul>
<li>2025 年最佳生物科技股票</li>
</ul>
<p><strong>查看我們關於再生元製藥的最新研究報告</strong></p>
<h2>再生元製藥股票表現</h2>
<p>再生元製藥的股票在週一開盤價為 591.99 美元。該股票的 50 日移動平均價格為 567.77 美元，200 日移動平均價格為 574.26 美元。該公司的市值為 627.5 億美元，市盈率為 14.92，市盈增長比率為 1.98，貝塔值為 0.35。該公司的債務與股本比率為 0.09，速動比率為 3.72，流動比率為 4.60。再生元製藥的股票在過去一年中的最低價為 476.49 美元，最高價為 1,154.56 美元。</p>
<ul>
<li>3 只擁有堅實資產負債表的股票，適合長期穩定投資</li>
</ul>
<p>再生元製藥（NASDAQ:REGN - 獲取免費報告）最近在 8 月 1 日星期五發布了季度財報。這家生物製藥公司報告的季度每股收益為 12.89 美元，超出市場共識預期的 8.43 美元，超出幅度為 4.46 美元。該公司季度收入為 36.8 億美元，而分析師預期為 33 億美元。再生元製藥的股本回報率為 15.06%，淨利潤率為 31.37%。再生元製藥的季度收入同比增長 3.6%。在去年同期，該公司每股收益為 11.56 美元。整體來看，賣方分析師預計再生元製藥將在當前財政年度發佈 35.92 美元的每股收益。</p>
<h2>再生元製藥宣佈分紅</h2>
<p>該公司最近還宣佈了季度分紅，已於 9 月 3 日星期三支付。8 月 18 日星期一的登記投資者獲得了每股 0.88 美元的分紅。該分紅的除息日期為 8 月 18 日星期一。這代表着每年 3.52 美元的分紅，收益率為 0.6%。再生元製藥的派息比率為 8.87%。</p>
<h2>再生元製藥簡介</h2>
<p>（免費報告）</p>
<p>再生元製藥公司在全球範圍內發現、發明、開發、生產和商業化治療各種疾病的藥物。該公司的產品包括用於治療濕性年齡相關性黃斑變性和糖尿病性黃斑水腫的 EYLEA 注射劑；近視性脈絡膜新生血管；糖尿病視網膜病；新生血管性青光眼；以及早產兒視網膜病。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過再生元製藥</li>
<li>2022-2025 年股市假期 - 紐約證券交易所和納斯達克的休市時間</li>
<li>GameStop 像 2021 年一樣狂歡：2025 年反彈背後的原因是什麼？</li>
<li>金融服務股票投資</li>
<li>3 只被忽視的價值股，預計在利率下降時大幅上漲</li>
<li>最活躍的股票：美元交易量與股數交易量</li>
<li>Hims &amp; Hers 股票因醫療保健降息狂潮而推高至新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在再生元製藥嗎？</h2>
<p>在你考慮再生元製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而再生元製藥並不在名單上。</p>
<p>雖然再生元製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

再生元制藥

<p>Founders Capital Management LLC 在第二季度將其在再生元製藥（Regeneron Pharmaceuticals, Inc.，NASDAQ:REGN）的持股增加了 7.0%，目前持有 8,274 股，價值 434 萬美元。其他機構投資者也顯著增加了他們的持倉。分析師對 REGN 的評級意見不一，普遍評級為 “適度買入”，目標價為 817.67 美元。再生元公佈了強勁的第二季度財報，每股收益（EPS）為 12.89 美元，超出預期。公司宣佈每股派發季度股息 0.88 美元，將於 9 月 3 日支付</p>

<p>Founders Capital Management LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,274 shares of the biopharmaceutical company's stock after purchasing an additional 538 shares during the quarter. Regeneron Pharmaceuticals makes up 0.7% of Founders Capital Management LLC's investment portfolio, making the stock its 25th largest position. Founders Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $4,344,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Founders Capital Management LLC 在最近向證券交易委員會提交的文件中表示，在第二季度將其在再生元製藥公司（NASDAQ:REGN - 免費報告）的持股增加了 7.0%。這家機構投資者在該季度額外購買了 538 股後，持有該生物製藥公司 8,274 股股票。再生元製藥佔 Founders Capital Management LLC 投資組合的 0.7%，是其第 25 大持股。到最近一個季度末，Founders Capital Management LLC 在再生元製藥的持股價值為 4,344,000 美元。</p>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大熊：3 只接近一年低點的股票，可能在 2025 年大幅上漲</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also modified their holdings of REGN. GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares in the last quarter. Nuveen LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $343,764,000. Pacer Advisors Inc. grew its position in Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after purchasing an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after purchasing an additional 303,785 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $127,215,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者也調整了對 REGN 的持股。GAMMA Investing LLC 在第一季度將其在再生元製藥的持股增加了 89,825.0%。GAMMA Investing LLC 目前持有 815,620 股該生物製藥公司的股票，價值 517,291,000 美元，此前在上個季度額外購買了 814,713 股。Nuveen LLC 在第一季度購買了再生元製藥的新頭寸，價值 343,764,000 美元。Pacer Advisors Inc.在第一季度將其在再生元製藥的持股增加了 2,296.9%。Pacer Advisors Inc.目前持有 407,370 股該生物製藥公司的股票，價值 258,366,000 美元，此前在上個季度額外購買了 390,374 股。Assenagon Asset Management S.A.在第一季度將其在再生元製藥的持股增加了 171.0%。Assenagon Asset Management S.A.目前持有 481,389 股該生物製藥公司的股票，價值 305,311,000 美元，此前在上個季度額外購買了 303,785 股。最後，Universal Beteiligungs und Servicegesellschaft mbH 在第四季度購買了再生元製藥的新頭寸，價值 127,215,000 美元。目前 83.31% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>REGN has been the subject of a number of recent analyst reports. Wells Fargo &amp; Company downgraded Regeneron Pharmaceuticals from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and set a $580.00 target price for the company. in a report on Friday, August 1st. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a &#34;buy&#34; rating for the company in a report on Monday, August 11th. Citigroup restated a &#34;buy&#34; rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Jefferies Financial Group raised their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, August 27th. Finally, Argus cut Regeneron Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, June 30th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $817.67.</p>
<div class="lb-trans"><p>REGN 最近受到了一些分析師報告的關注。富國銀行將再生元製藥的評級從 “增持” 下調至 “持平”，併為該公司設定了 580.00 美元的目標價。在 8 月 1 日星期五的報告中，Truist Financial 將再生元製藥的目標價從 940.00 美元下調至 812.00 美元，並在 8 月 11 日星期一的報告中為該公司設定了 “買入” 評級。花旗集團在 8 月 1 日星期五的研究報告中重申了 “買入” 評級，併為再生元製藥的股票發佈了 650.00 美元的目標價。傑富瑞金融集團在 8 月 27 日星期三的研究報告中將再生元製藥的目標價從 813.00 美元上調至 831.00 美元，並給予該公司 “買入” 評級。最後，Argus 在 6 月 30 日星期一的研究報告中將再生元製藥的評級從 “買入” 下調至 “持有”。三位研究分析師對該股票給予了強烈買入評級，十八位給予了買入評級，六位給予了持有評級，一位給予了賣出評級。根據 MarketBeat，該公司目前的共識評級為 “適度買入”，共識目標價為 817.67 美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物科技股票</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on Regeneron Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於再生元製藥的最新研究報告</strong></p>
</div><h2>Regeneron Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>再生元製藥股票表現</h2>
</div><p>Regeneron Pharmaceuticals stock opened at $591.99 on Monday. The stock's 50 day moving average price is $567.77 and its 200 day moving average price is $574.26. The firm has a market capitalization of $62.75 billion, a PE ratio of 14.92, a price-to-earnings-growth ratio of 1.98 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,154.56.</p>
<div class="lb-trans"><p>再生元製藥的股票在週一開盤價為 591.99 美元。該股票的 50 日移動平均價格為 567.77 美元，200 日移動平均價格為 574.26 美元。該公司的市值為 627.5 億美元，市盈率為 14.92，市盈增長比率為 1.98，貝塔值為 0.35。該公司的債務與股本比率為 0.09，速動比率為 3.72，流動比率為 4.60。再生元製藥的股票在過去一年中的最低價為 476.49 美元，最高價為 1,154.56 美元。</p>
</div><ul>
<li>3 Stocks With Ironclad Balance Sheets for Long-Term Stability</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只擁有堅實資產負債表的股票，適合長期穩定投資</li>
</ul>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $11.56 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>再生元製藥（NASDAQ:REGN - 獲取免費報告）最近在 8 月 1 日星期五發布了季度財報。這家生物製藥公司報告的季度每股收益為 12.89 美元，超出市場共識預期的 8.43 美元，超出幅度為 4.46 美元。該公司季度收入為 36.8 億美元，而分析師預期為 33 億美元。再生元製藥的股本回報率為 15.06%，淨利潤率為 31.37%。再生元製藥的季度收入同比增長 3.6%。在去年同期，該公司每股收益為 11.56 美元。整體來看，賣方分析師預計再生元製藥將在當前財政年度發佈 35.92 美元的每股收益。</p>
</div><h2>Regeneron Pharmaceuticals Announces Dividend</h2>
<div class="lb-trans"><h2>再生元製藥宣佈分紅</h2>
</div><p>The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度分紅，已於 9 月 3 日星期三支付。8 月 18 日星期一的登記投資者獲得了每股 0.88 美元的分紅。該分紅的除息日期為 8 月 18 日星期一。這代表着每年 3.52 美元的分紅，收益率為 0.6%。再生元製藥的派息比率為 8.87%。</p>
</div><h2>Regeneron Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>再生元製藥簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.</p>
<div class="lb-trans"><p>再生元製藥公司在全球範圍內發現、發明、開發、生產和商業化治療各種疾病的藥物。該公司的產品包括用於治療濕性年齡相關性黃斑變性和糖尿病性黃斑水腫的 EYLEA 注射劑；近視性脈絡膜新生血管；糖尿病視網膜病；新生血管性青光眼；以及早產兒視網膜病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound?</li>
<li>Financial Services Stocks Investing</li>
<li>3 Overlooked Value Stocks Set to Surge as Rates Drop</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Hims &amp; Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過再生元製藥</li>
<li>2022-2025 年股市假期 - 紐約證券交易所和納斯達克的休市時間</li>
<li>GameStop 像 2021 年一樣狂歡：2025 年反彈背後的原因是什麼？</li>
<li>金融服務股票投資</li>
<li>3 只被忽視的價值股，預計在利率下降時大幅上漲</li>
<li>最活躍的股票：美元交易量與股數交易量</li>
<li>Hims &amp; Hers 股票因醫療保健降息狂潮而推高至新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在再生元製藥嗎？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮再生元製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而再生元製藥並不在名單上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然再生元製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Founders Capital Management LLC 購買了再生元製藥公司 $REGN 的股份